April 21, 2017 / 2:36 PM / 8 months ago

BRIEF-Merck reports results from real-world observational study in U.S. Veterans Affairs System evaluating use of ZEPATIER

April 21 (Reuters) - Merck & Co Inc :

* Real-World observational study in the U.S. Veterans Affairs System evaluating use of Merck’S ZEPATIER® (Elbasvir and Grazoprevir) shows high sustained virologic response rates in patients with chronic Hepatitis C

* For evaluable population, 95.6 percent of veterans treated with ZEPATIER achieved primary outcome of sustained virologic response Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below